Cellectis S.A. Net Income 2011-2026 | CLLS

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Cellectis S.A.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-125 M	-81.1 M	-115 M	-88.3 M	-104 M	-64.1 M	-22.5 M	24.3 K	-84.3 M	-29.5 M	-30.9 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
24.3 K	-125 M	-67.7 M

Quarterly Net Income Cellectis S.A.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-41.6 M	-	-	-	-35.9 M	-	-	-	-36.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-35.9 M	-41.6 M	-38 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
Biogen BIIB	1.63 B	$ 172.65	0.62 %	$ 25.1 B	USA
MorphoSys AG MOR	-514 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	-33.4 M	$ 2.38	-4.22 %	$ 134 M	China
Acorda Therapeutics ACOR	-253 M	-	-24.86 %	$ 820 K	USA
BioNTech SE BNTX	10.3 B	$ 117.22	1.07 %	$ 27.2 B	Germany
Aptorum Group Limited APM	-4.27 M	$ 0.98	1.35 %	$ 5.34 M	China
Alterity Therapeutics Limited ATHE	-12.8 M	$ 3.62	1.91 %	$ 8.71 B	Australia
Alexion Pharmaceuticals, Inc. ALXN	603 M	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-31.2 M	-	-13.47 %	$ 169 M	France
Catalyst Biosciences CBIO	-85.5 M	$ 12.1	-5.47 %	$ 797 M	USA
Midatech Pharma plc MTP	-5.46 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.09 M	-	-1.52 %	$ 24.7 M	USA
Akero Therapeutics AKRO	-252 M	-	-	$ 3.67 B	USA
BioXcel Therapeutics BTAI	-59.6 M	$ 1.78	-2.47 %	$ 4.51 M	USA
BioLineRx Ltd. BLRX	-27.1 M	$ 3.05	-1.77 %	$ 908 M	Israel
Applied Molecular Transport AMTI	-126 M	-	-	$ 10.1 M	USA
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
Ascendis Pharma A/S ASND	-384 M	$ 232.9	-1.06 %	$ 5 B	Danmark
Burford Capital Limited BUR	172 M	$ 9.73	-0.21 %	$ 1.57 B	Britain
ARCA biopharma ABIO	-83.7 M	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	-9.57 M	-	4.01 %	$ 150 M	Canada
Arrowhead Pharmaceuticals ARWR	-1.63 M	$ 67.14	0.13 %	$ 8.98 B	USA
Compugen Ltd. CGEN	-14.2 M	$ 2.05	-1.91 %	$ 184 M	Israel
Can-Fite BioPharma Ltd. CANF	-7.88 M	$ 4.4	-2.87 %	$ 9.57 B	Israel
Aeterna Zentaris AEZS	-8.37 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-14.8 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-208 M	-	-	$ 1.01 B	USA
Akouos AKUS	-86.7 M	-	0.23 %	$ 488 M	USA
Adaptimmune Therapeutics plc ADAP	-114 M	-	-15.15 %	$ 60.3 M	Britain
Amphastar Pharmaceuticals AMPH	160 M	$ 26.56	2.45 %	$ 1.29 B	USA
Coherus BioSciences CHRS	-238 M	$ 2.25	9.22 %	$ 212 M	USA
Amneal Pharmaceuticals AMRX	-73.9 M	$ 13.58	1.42 %	$ 4.2 B	USA
AIkido Pharma AIKI	-14.7 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	-34 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Aptose Biosciences APTO	-25.4 M	-	-45.71 %	$ 1.2 M	Canada
Acer Therapeutics ACER	-26.2 M	-	2.71 %	$ 14 M	USA
Aravive ARAV	-76.3 M	-	-13.39 %	$ 1.45 M	USA
Alpine Immune Sciences ALPN	-57.8 M	-	-	$ 2.17 B	USA
AlloVir ALVR	-58.8 M	-	4.14 %	$ 49.1 M	USA
Athira Pharma ATHA	-96.9 M	-	-	$ 269 M	USA
Ampio Pharmaceuticals AMPE	-8.63 M	-	-11.43 %	$ 502 K	USA
Celldex Therapeutics CLDX	-158 M	$ 26.54	2.41 %	$ 1.71 M	USA
AVROBIO AVRO	12.2 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	-38 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	-13.6 M	$ 2.75	1.84 %	$ 17.3 M	USA
AstraZeneca PLC AZN	115 M	$ 94.2	1.34 %	$ 96.9 B	Britain
Arena Pharmaceuticals ARNA	-616 M	-	-6.81 %	$ 3.04 B	USA
Brickell Biotech BBI	-5.69 M	-	-5.38 %	$ 6.06 M	USA